Celltrion and Teva announced that the FDA has approved Herzuma (trastuzumab-pkrb) injection, a new biosimilar to Herceptin (trastuzumab; Genentech) for certain HER2-overexpressing breast cancer indications.
from Latest articles from Cancer Therapy Advisor News http://bit.ly/2Rkyujq
from Latest articles from Cancer Therapy Advisor News http://bit.ly/2Rkyujq